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Abstract WT1 encodes a zinc finger protein with a key role in 
urogenital development that is inactivated in a subset of Wilms' 
tumors. This tumor suppressor gene product contains an amino- 
terminal dimerization domain required for trans-inhibition of 
wild-type WT1 activity by mutants defective for DNA binding. 
In the course of characterizing truncation mutants of WT1, we 
noted that the WT1 zinc fingers contain two functionally 
independent argeting signals required for nuclear localization 
of the protein. These novel signals lie within zinc fingers I and 
within zinc f'mgers II and Ill. We demonstrate that nuclear 
targeting of the WT1 homodimerization domain functionally 
antagonizes activity of the wild-type protein activity. 
Key words: WT1; Nuclear localization; Denys-Drash 
syndrome; Wilms' tumor; WT1 gene 
I. Introduction 
Wilms' tumor (WT) is an embryonic ancer which presents 
either sporadically or in the context of genetic susceptibility, 
generally before the age of 5 years [1]. It accounts for ,-~ 5% of 
pediatric tumors and has been extensively studied to deter- 
mine how deregulation of the urogenital developmental pro- 
gram leads to cancer initiation. Although most cases of WT 
are sporadic, ~ 5-10% show a genetic predisposition and of- 
ten occur in association with congenital defects [1]. An 1 lp13 
WT suppressor gene, wtl, has been extensively characterized 
and is implicated by mutational analysis in 10-15% of spora- 
dic WTs [2M], in some familial WT cases [5], and as playing a 
role in initiation of this disease [6]. 
The wtl gene encodes a protein having many characteristics 
of a transcription factor: a glutamine/proline-rich amino-ter- 
minus [7,8], nuclear localization [9], and four Cys2_-Hisz zinc 
finger motifs. The three WT1 carboxy-terminal zinc fingers 
show 64% identity to the three zinc fingers of the early growth 
response gene-1 (EGR-1) [7,8]. The mRNA contains two alter- 
native sites of translation initiation [10], two alternatively 
spliced exons [11,12], and undergoes RNA editing [13], thus 
potentially encoding 16 different protein isoforms with pre- 
dicted molecular masses of 52-65 kDa. The function of the 
alternative translation initiation event, or of the first alterna- 
tively spliced exon (exon V), has not been well defined, 
although exon V can repress transcription when fused to a 
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heterologous DNA binding domain [14]. Splicing of the sec- 
ond alternatively spliced exon (IX) inserts or removes three 
amino acids (+/-KTS)  between zinc fingers III and IV and 
changes the DNA binding specificity of the protein. 
WT1 isoforms can bind to two DNA motifs, albeit with 
different affinities: (1) a GC-rich motif with the conserved 
feature, 5'-GC/yGGGGGAG/c-3', similar to the EGR-1 bind- 
ing site [15], and (2) a (TCC)n containing sequence, 5'- 
TCCTCCTCCTCCTCTCC-3' [16]. A number of genes in- 
volved in growth regulation and cellular differentiation con- 
tain these binding sites in their promoters and are thought o 
be regulated by WT1. These include insulin-like growth factor 
II, insulin-like growth factor 1 receptor, platelet-derived 
growth factor A-chain, colony stimulating factor-l, trans- 
forming growth factor-131, retinoic acid receptor-a, Pax-2, c- 
myb, epidermal growth factor receptor, and the wtl gene itself 
(for a review, see [17]). The wtl gene product has the potential 
to mediate both transcriptional repression and activation [17]. 
An essential role for WT1 in the development of the uro- 
genital system has been inferred from its normal expression 
pattern [9,18], failure of this system to develop in wtl-null 
mice [19], and aberrant differentiation of this system in chil- 
dren with germline wtl mutations ([5,20], for a review see 
[21]). Male children in which one wtl allele is deleted as part 
of the WAGR (WT/Aniridia/Genitourinary (GU) anomalies/ 
Retardation) syndrome often are born with mild genitourin- 
ary defects (i.e., undescended testis and hypospadias). On the 
other hand, children with Denys-Drash syndrome (DDS) have 
much more severe developmental disorders of the reproduc- 
tive system, as well as a characteristic renal nephropathy oc- 
curring generally with the first 2 years of life [21]. The major- 
ity of DDS individuals harbor wtl missense mutations within 
zinc fingers II and III which are thought o behave in a domi- 
nant-negative fashion [20,21]. Consistent with this idea is the 
recent demonstration that WT1 can oligomerize, that mutant 
WT1 protein can antagonize activity of wild-type protein 
[22,23], and that some WT1 missense mutations in WTs ap- 
pear to be in a heterozygous configuration [2,4,11]. 
Recently, Larsson et al. [24] demonstrated that different 
WT1 isoforms localize to distinct compartments of the 
nucleus - -  with -KTS  isoforms displaying a distribution 
that parallels that of classical transcription factors such as 
Spl and TFIIB - -  whereas +KTS isoforms are preferentially 
associated with interchromatin granules and coiled bodies. 
These results were recently extended by Englert et al. [25] 
who demonstrated that overexpression of a WT1 truncation 
mutant lacking the four zinc finger domains could alter the 
subnuclear localization of WTI ( -KTS) .  In this report, we set 
out to define the nuclear localization signal(s) of WT1 and 
demonstrate that subcellular localization of the WT1 homo- 
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dimerization domain affects the efficiency by which it can 
behave in a dominant-negative fashion. Our results identify 
two nuclear localization domains: one within zinc finger I and 
one within zinc fingers II and III. 
2. Materials and methods 
2.1. Cell culture and transfections 
NIH 3T3 and COS-7 cells were maintained in DMEM containing 
high glucose plus 10% fetal calf serum (Gibco-BRL). Transfection of 
NIH-3T3 cells was performed by calcium phosphate precipitation [26], 
whereas transfection ofCOS-7 cells was performed by electroporation 
[9]. 
2.2. DNA constructs 
CMV-based murine WT1 expression vectors were generated by li- 
gating a 1441 bp Sau 3AI WT1 eDNA fragment (containing 42 bp of 
5' untranslated region, the coding region, and 109 bp of 3' UTR) into 
the BamHI site of pgTat-CMV3 [9]. CMV-hWT(+/-) was generated 
by cleavage of the human WTI cDNA with SacII (which cleaves 31 
bp upstream of the initiator ATG), repairing with T4 DNA polymer- 
ase, followed by ligation to BglII linkers (5'-GGAAGATCTTCC-3'). 
The hWT1 cDNA was then digested with EcoRI (which cleaves in the 
pKS polylinker, 11 bp downstream of the TGA codon), Klenow re- 
paired, and digested with BglII. The eDNA insert was then direction- 
ally cloned into the BamHIlXhoI (Klenow repaired) sites of pgTat- 
CMV3. Expression vectors carrying WT1 mutations previously iden- 
tified in DDS or hereditary WT patients were generated by PCR- 
mediated mutagenesis and confirmed by direct sequencing. Details 
as to the construction of these deletion vectors can be obtained 
from the author upon request. 
2.3. CA T and ~-galactosidase assays 
Forty-eight hours after transfection, cells were harvested and lysed 
in 0.25 M Tris-HC1 (pH 8.0)/0.1% Nonidet-P40. The cellular debris 
was pelleted and the lysate assayed for I~-galactosidase ctivity with 
chlorophenol red ~-o-galactopyranoside (Bo hringer Mannheim) [26]. 
Following standardization for !3-galactosidase activity, extracts were 
assayed for CAT activity using [14C]chloramphenicol (Amersham) 
followed by thin layer chromatography [26]. The position of acetyl- 
ated and non-acetylated chloramphenicol was identified by autoradio- 
graphy and CAT activity was calculated by excision of the respective 
products from the TLC plate followed by scintillation counting. 
Subcellular fractions were prepared essentially as described by 
Dignam et al. [27]. Nuclear and cytoplasmic fractions were boiled in 
2% SDS for 10 min and the insoluble material removed by centrifuga- 
tion in a microfuge at 4°C for 10 min. Equivalent cell amounts of each 
supernatant was fractionated by SDS-PAGE, transferred to Immobi- 
lon-P (Millipore Corp.) and probed with the indicated antibodies. 
Visualization was performed with Renaissance hemiluminescence re- 
agents (Dupont NEN). The anti-WT1 antibody 180 (directed against 
the first 180 amino acids of WT1) was purchased from Santa Cruz 
Biotechnology. 
2.4. Immunofluorescence and ~l-galactosidase staining 
Cells were seeded onto coverslips and transfected with wtl expres- 
sion vectors. Forty-eight hours later the cells were washed in cold 
PBS, fixed for 20 min in 3.7% formaldehyde/PBS and 5 min at 
-20°C in methanol. The cells were pre-blocked with 10% goat ser- 
um/l% bovine serum albumin/0.3% Triton X-100 for 1 h, then probed 
with the indicated antibody for 4 h. The antibody was visualized with 
an anti-rabbit goat antibody conjugated toTexas Red (Jackson Labs). 
Cover slips were examined under a Zeiss immunofluorescent micro- 
scope and photographed with TMax 400 film (Kodak). 
For 13-galactosidase staining, transfected cells were washed in PBS 
and fixed in 2% paraformaldehyde/0.2% glutaraldehyde for 1 min. 
The cells were stained at 37°C for 24 h with 1 mg/ml 5-bromo-4- 
chloro-3-indolyl-[EI-D-galactoside (X-gal) in 5 mM potassium ferrous 
cyanide, 5mM potassium ferric cyanide, 2mM MgC12. After staining, 
the cells were fixed with 3.7% formaldehyde for 5 rain, dehydrated 
with ethanol, and counterstained with Eosin Y (Sigma). Coverslips 
were examined under bright light with a Zeiss Axioskop and photo- 
graphed with TMax 400 film (Kodak). 
3. Results 
Previous work from our laboratory had demonstrated that 
WT1 is located exclusively within the nucleus despite the ab- 
sence of an identifiable nuclear localization signal [9,28]. Sub- 
sequently, Larrson et al. [24] demonstrated that alternative 
splicing within the WT1 zinc fingers alters the subnuclear 
distribution profile of the WT1 isoforms. In this report, we 
undertook to identify the signal(s) responsible for WT1 nucle- 
ar targeting. 
3.1. The WT1 nucleic acid binding domain harbors two nuclear 
localization signals 
To identify the region necessary for nuclear targeting of the 
WT1 protein, a small number of synthetic deletion mutants, 
CMV-D3, CMV-D4, and CMV-S1, were generated within the 
carboxy-terminal domain of WT1 (Fig. 1A). CMV-D3 and 
CMV-D4 were generated from the murine WTI ( - / - )  
cDNA, whereas CMV-S1 was generated from the human 
WTI (+/ - )  eDNA. Since both the human and murine WT1 
isoforms localize to the nucleus [9,24,28] and the protein pro- 
duct from both species are more than 96% identical, we do 
not expect differences in behaviour between the murine and 
human gene products. Immunofluorescence studies on NIH 
3T3 cells transfected with these constructs demonstrated that 
whereas wild-type WT1 protein concentrated to the nucleus, 
the protein the product of CMV-D3 was present in both the 
cytoplasm and the nucleus (Fig. 2A). Deletion of zinc fingers 
III and IV (CMV-D4) or zinc fingers I I - IV (CMV-S1) pro- 
duced mutants till capable of targeting to the nucleus (Fig. 
2A). These results indicate that nuclear localization is not a 
secondary consequence of WT1 binding to DNA. 
We and others have previously described a number of mis- 
sense and nonsense mutations in the wtl gene occurring in 
individuals with WT and urogenital system anomalies [21]. 
Some of these mutations occur in individuals with WT and 
hypospadias and/or cryptorchidism, but without the renal ne- 
phropathy characteristic of DDS, and are thus thought o be 
loss of function mutations (CMV-P.G., CMV-T.S., CMV-10). 
Others occur in individuals with renal nephropathy, WT, and 
genital system anomalies that are much more severe than ob- 
served in WAGR syndrome and are thus thought o behave in 
a dominant-negative fashion (CMV-P.M.) [21]. Still others 
occur in individuals who have been classified as incomplete 
DDS, since they do not show the complete triad of malforma- 
tions generally associated with DDS (CMV-C.N., CMV-S.L.) 
[21], and the classification of these mutants is not clear. In 
order to begin the biochemical characterization f these mu- 
tants, several were rebuilt into the context of the human 
WTI (+/ - )  cDNA (Fig. 1A). When introduced into NIH 
3T3 cells, none of these mutant products were capable of 
concentrating in the nucleus, consistent with the data pre- 
sented above. In considering the data obtained with CMV- 
T.S. and CMV-S1, our results indicate that a nuclear localiza- 
tion signal(s) lies between amino acids 291 and 350 of the 
WT1 polypeptide, possibly within the first zinc finger domain. 
This conclusion was substantiated by preparing nuclear and 
cytoplasmic fractions of COS-7 cells transfected with the var- 
ious deletion mutants and analyzing the subcellular localiza- 
tion of WT1 by Western blotting (Fig. 2B). Greater than 95% 
of Spl was present in the nuclear fraction of extracts prepared 
from CMV-WTI ( - / - )  or CMV-D3 transfected COS cells 
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Fig. 1. Expression vectors used for subcellular localization of WT1. 
Schematic diagram of murine and human wtl expression vectors 
used in this study. The absence or presence of alternatively spliced 
exons is indicated by a ( - )  or (+) sign, respectively. Amino acid po- 
sitions demarcating the boundary of the deletions are indicated 
above each construct. The blackened box denotes the CMV promo- 
ter, the stippled boxes denote the wtl zinc fingers, the first alterna- 
tively spliced exon is represented by a coarse dotted box. In situa- 
tions where missense mutations result in a frameshift shift, the 
novel open reading frame is denoted by a dotted box. The amino 
acid position of the predicted frameshift is denoted above the cod- 
ing region. The start site of transcription is denoted by a right- 
angled arrow. For those mutations identified in individuals with 
WTs and genitourinary anomalies, the associated phenotype is pre- 
sented on the right: N/A, not applicable; WT, Wilms' tumor; WT b, 
bilateral WT; Hyp, hypospadias; Cry, cryptorchidism; Cry b, bilat- 
eral cryptorchidism; Nephr., renal nephropathy; XY¢, XY pseudo- 
hermaphroditism. A detailed escription of these mutations and the 
associated phenotypes can be found in the following references: 
CMV-P.G. [5]; CMV-C.N. [34]; CMV-T.S. [5]; CMV-S.L. [34]; 
CMV-P.M. [35]; CMV-10 (patient 10 in [36]). The predicted mode 
of behaviour of each mutation is also indicated: L/F, loss of func- 
tion; D/N, dominant-negative; ???, unclear. Since patient C.N. has 
had nephrotic syndrome with minimal change and eventually re- 
gained normal renal function [37], and patient S.L. developed renal 
nephropathy at the age of 15 years, these patients have been classi- 
fied as incomplete DDS. For the current study, we have not drawn 
conclusions about the nature of their mutations. Also summarized 
to the right are the subcellular localization of the deletion mutants 
from immunofluorescence and cell fractionation studies detailed in 
Fig. 2. 
(Fig. 2B, bottom panel), confirming the integrity of the nucle- 
ar preparations. Introduction of CMV-WTI ( - / - )  into COS-7 
cells (Fig. 2B) resulted in the nuclear targeting of more than 
90% of the protein (Fig. 2B, compare lane 2 to 1). Similar 
results were obtained with CMV-hWT(+/-)  (data not shown). 
However, deletion of amino acids 262-364 produced a poly- 
peptide no longer capable of concentrating in the nucleus 
(compare lanes 3 and 4). Since polypeptides having molecular 
masses less than 40--50 kDa can passively diffuse into the 
nucleus [29], we cannot exclude the possibility that nuclear 
localization of the D3 polypeptide product is due to diffusion. 
This issue will be experimentally addressed below. All trunca- 
tion mutants which terminated before the zinc finger domain 
produced polypeptides which were present in both the cyto- 
plasmic and the nuclear fractions, formally demonstrating 
that these mutants had lost their ability to concentrate in 
the nucleus (lanes 5-16). 
To assess the possibility that a nuclear localization do- 
main(s) was present within the WT1 zinc fingers, a series of 
fusion proteins were generated between the WT1 zinc fingers 
and 15-galactosidase (Fig. 3A). Since the molecular mass of the 
fusion products is greater than 116 kDa and 15-galactosidase 
does not contain a nuclear targeting signal, nuclear targeting 
should be dependent on the presence of an active signal within 
the polypeptide molecule. Following transfection of these con- 
structs into COS cells, 13-galactosidase localization was deter- 
mined by direct measurement of enzyme activity (Fig. 3B). 
Whereas 15-galactosidase failed to concentrate in the nucleus, 
fusion of the four WT1 zinc fingers produced a polypeptide 
capable of nuclear targeting (p27; Fig. 3B). In addition, fu- 
sion of only zinc finger I (pl) or zinc fingers II and III to 15- 
galactosidase (p65) produced polypeptides also capable of nu- 
clear targeting (Fig. 3B), indicating the existence of two separ- 
able nuclear targeting signals: one in zinc finger I and the 
other in zinc fingers II and/or III. Interestingly, fusion of 
zinc fingers III and IV to 15-galactosidase produced a fusion 
molecule not capable of nuclear targeting (p5; Fig. 3B), sug- 
gesting that the presence of a zinc finger per se is not sufficient 
for this behaviour. 
3.2. Nuclear targeting is necessary for antagonistic activity by 
WT1 mutants 
We have previously developed a trans-dominant inhibition 
assay in which DDS alleles, when co-transfected with wild- 
type WT1 and an appropriate reporter construct, functions in 
trans to prevent ranscriptional repression by WT1 (Fig. 4) 
[23]. Necessary for trans-inhibition is the presence of the 
WT1 multimerization domain which lies within the first 160 
amino acids of the protein [22,23]. WT1 mutants defective for 
DNA binding, but still retaining the potential for nuclear 
localization (CMV-WTl/(a94R/W) and CMV-S1), are capable 
of trans-dominant inhibition of wild-type WT1 activity in this 
assay (Fig. 4). The deletion mutant, CMV-P.G., defective for 
nuclear localization but still capable of multimerization, was 
unable to effectively trans-inhibit wild-type WT1 activity in 
this assay (Fig. 4B). To directly test whether this was due to 
decreased efficiency of nuclear targeting, we produced a chi- 
meric fusion whereby the SV40 nuclear localization signal, 
KKKRKVE, was positioned at the carboxy-terminus of the 
WT1 dimerization domain (Fig. 4A). This mutant, CMV- 
ABsu36I was targeted to the nucleus (W.B., data not shown) 
and was capable of partial trans-dominant inhibition of wild- 
type WT1 activity (Fig. 4B). We conclude that deletion mu- 
tants which lack nuclear targeting ability cannot inhibit activ- 
ity of wild-type WT1 protein in trans as effectively as missense 
mutations which disrupt DNA binding but not nuclear target- 
ing. 
4. Discussion 
In this report, we demonstrate he presence of two distinct 
nuclear localization signals within the DNA binding domain 
of the WT1 protein (Figs. 2 and 3). Our results indicate that 
nuclear localization is distinct from DNA binding since mu- 
tants impaired for DNA binding can still localize to the nu- 
cleus (Fig. 2; CMV-D4). Protein nuclear localization signals 
(NLS) are generally characterized by one or more clusters of 
basic amino acids, although no clear consensus equence has 
emerged (for a review, see ref. [30]). Although a number of 
basic residues are present in the WT 1 zinc fingers, they can be 
found in all four fingers and no obvious consensus exists with 
previously identified nuclear targeting signals [30]. We have 
yet to identify the core sequence motif within finger I and 
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Fig. 2. Elmmunofluorescence and cell fractionation studies of WT1 
deletion mutants. (A) NIH 3T3 cells were transfected with wtl ex- 
pression plasmids and the protein products detected with the anti- 
WTI antibody 180 by indirect immunofiuorescence. The expression 
vector used in each transfection is indicated below each representa- 
tive panel. (B) Fractionation of cytoplasmic and nuclear extracts 
prepared from COS-7 cells transfected with wtl expression vectors. 
Equivalent cell numbers of cytoplasmic and nuclear extracts were 
fractionated on a 10% SDS-PAGE, followed by electrophoretic 
transfer to Immobilon-P. Blots were probed with the anti-WT1 anti- 
body 180 or with the anti-Spl antibody PEP2 (Santa Cruz), as pre- 
viously described [10]. Molecular weight standards are indicated to 
the left and are New England Biolabs prestained protein markers. 
Extracts were prepared from COS-7 cells transfected with the fol- 
lowing expression vectors. Top panel: lanes 1-2, CMV-WTI ( - / - ) ;  
lanes 3-4, CMV-D3; lanes 5~5, CMV-P.G.; lanes 7-8, CMV-C.N.; 
lanes 9-10, CMV-T.S.; lanes 11-12, CMV-S.L.; lanes 13-14, CMV- 
P.M.; lanes 15-16, CMV-10. The first four lanes of the bottom pan- 
el contain the same protein extracts as analyzed in the first four 
lanes of the top panel. C, cytoplasmic; N, nuclear. 
fingers II and III necessary for nuclear targeting of WT1. 
Recently, a functional receptor for nuclear localization se- 
quences, hSRPla,  has been identified and cloned [31]. This 
protein can bind both simple and bipartite NLS motifs and is 
thought o mediate the first step of nuclear import - -  that is, 
NLS-dependent docking of the substrate at the nuclear enve- 
lope [31]. Using in vitro synthesized protein, we failed to 
detect a protein-protein interaction between WTI and 
hSRPlct (S.C., data not shown), suggesting that a second, 
yet to be identified, receptor may mediate WT1 docking to 
the nuclear envelope. Consistent with this interpretation is the 
identification of at least one addition class of NLS receptors 
believed to mediate import of small nuclear ibonucleoprotein 
particles [32]. 
Patients with complete deletions of wtl (as in the WAGR 
syndrome) or with mutations that lead to truncation of the 
WT1 protein have been observed to have mild abnormalities 
of the genitourinary system, indicating that in humans, loss of 
one wtl allele perturbs development of this system. The sub- 
sequent discovery of germline missense mutations of wtl in 
patients with the severe phenotype of DDS suggested that 
these mutations act either in a dominant manner or as domi- 
nant-negatives (Fig. 4). The discovery of a splicing lesion in 
individuals with DDS supports the dominant-negative model, 
since the primary sequence of the WT1 isoforms in these in- 
dividuals are normal and unlikely to exhibit a gain of function 
[33]. Rather, it is likely that deregulation of the ratio of WT1 
isoforms is responsible for the observed phenotype. Further 
support for this theory was provided when it was shown that 
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WT1 can multimerize and that mutated WT1 can antagonize 
the function of wild-type WT1 [22,23]. Thus, in DDS individ- 
uals, the mutated WT1 is predicted to reduce the activity of 
WT1 to levels lower than those found in individuals with 
deletions of wtl, and thus produce more severe developmental 
anomalies. 
In this report, we demonstrate that WT1 truncation mu- 
tants, derived from individuals where the lesions have been 
postulated to result in a loss of function or to behave as 
dominant-negatives, failed to concentrate in the nucleus. 
These results indicate that differences in nuclear targeting can- 
not account for the differences in phenotypes observed among 
these individuals. We have measured the half-life of the dif- 
ferent runcation mutants in transfected COS-7 cells and have 
found no significant differences in among them (W. Bruening, 
data not shown). It is possible that differences in mRNA 
metabolism between the various mutants may be responsible 
for whether the mutants behave in a dominant-negative fash- 
ion or results in a loss of function, although this hypothesis 
remains to be tested. 
Two reports have documented differences in subnuclear lo- 
calization among WT1 isoforms [24,25]. Larsson et al. [24] 
demonstrated that the -KTS  isoforms localized primarily 
with DNA in transcription factor domains whereas the 
+KTS isoforms localized primarily with splicing factors. Eng- 
lert et al. [25] extended these results and demonstrated that 
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Fig. 3. The WTI zinc fingers harbor two independent nuclear trans- 
port signals. (A) Expression vectors containing the wtl zinc fingers 
fused to the [3-galactosidas reporter gene under control of the SV40 
promoter. The coarse dotted box represents the SV40 viral promo- 
ter, the blackened box symbolizes the 13-galactosidase coding region, 
and the stippled boxes are the wtl zinc fingers. The identity of the 
zinc finger(s) fused to ~-gal is indicated below each stippled box. 
Construct names are iindicated to the left. (B) COS-7 cells were 
transfected with the expression vectors in A and stained for I~-galac- 
tosidase activity. 
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Fig. 4. Nuclear localization is required for trans-dominant inhibition of wild-type WT1 activity. (A) Schematic representation of constructs 
used in the dominant-negative assay. The reporter gene used encodes CAT (zigzag box) under the control of the TK promoter containing two 
GAL4 binding sites (coarse dotted box). The WT1 region amino terminal of the zinc fingers is indicated by an open box and the GAlA bind- 
ing domain is represented by a hatched box. A variety of wtl alleles were introduced in trans to effect inhibition of WTI/GAL4 activity. CMV- 
VqTI(394R/Vq) contains the most common DDS mutation -- an arginine to tryptophan substitution i  zinc finger III (represented by a check- 
ered box) [20]. Construct ABsu 361 was generated by introducing an oligonucleotide containing the SV40 nuclear localization signal, followed 
by a stop codon, into the Bsu 36I/Avr II sites of CMV/WTI(-/-) .  (B) Trans-dominant repression assay of wtl expression vectors. The CAT 
activity produced by the reporter alone is defined as 100%. Ten micrograms of WT1/GAL4 was co-transfected with 5 ~tg of TK(GAL)/CAT 
and with 10 [tg of the indicated wtl alleles. Experiments were standardized for transfection efficiency by co-transfection with 2 I.tg of RSV/13-ga- 
lactosidase. All experiments were performed at least 3 times. Standard deviation between experiments i  indicated on the graph by error bars. 
All constructs produced approximately equal amounts of WT1 protein in a dose-dependent fashion as assayed by Western blotting (W.B., data 
not shown). 
duced a polypeptide which demonstrated predominantly a
nuclear speckling pattern. We note one interesting difference 
between our results and those of Englert et al. [25]. Whereas 
we find that deletions of  zinc fingers I and II produced a 
polypeptide no longer capable of concentrating in the nucleus 
(Fig. 2, CMV-D3), Englert et al. [25] have demonstrated that 
deletions of all four zinc fingers are not required for nuclear 
localization. Since CMV-D3 also removed amino acids up- 
stream of zinc finger 1, we interpret hese results to indicate 
the possible existence of an additional nuclear localization 
domain immediately amino-terminal of the first zinc finger. 
We have not tested this region independently as a fusion to 
13-galactosidase to determine if it is sufficient o impart nuclear 
localization, although the results of Englert et al. [25] would 
suggest his to be the case. The presence of several, independ- 
ently functional, nuclear targeting motifs at the carboxyl-ter- 
minus of WT1 may suggests that frameshifts or nonsense 
mutants with at least one NLS function differently from 
frameshift or nonsense mutants without an NLS in usurping 
normal WT1 activity. Our results showing that artificially im- 
parting a NLS to the WT1 dimerization domain improves the 
efficiency with which trans-inhibition of wild-type wtl activity 
occurs, is consistent with this hypothesis. Deletion mutants 
lacking an NLS may function by sequestering wild-type 
WT1 protein in the cytoplasm. 
In summary, our results demonstrate the presence of  at 
least two separable NLS within the WT1 zinc fingers (Figs. 
2 and 3). Mutants with impaired nuclear targeting are no 
longer capable of efficient trans-inhibition of wild-type WT1 
activity (Fig. 4), and likely affect development of  the urogen- 
ital system through other mechanisms. 
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